目的 探討咳喘舒片聯(lián)合布地奈德福莫特羅吸入粉霧劑治療支氣管哮喘的臨床療效。方法 選擇2020年2月-2021年2月在天津?qū)幒訁^(qū)醫(yī)院治療的102例支氣管哮喘患者為研究對象，采用雙色球法分為對照組和治療組，每組各51例。對照組吸入布地奈德福莫特羅吸入粉霧劑（Ⅱ），2吸/次，必要時(shí)增至4吸，2次/d；治療組在對照組的基礎(chǔ)上口服咳喘舒片，1 g/次，3次/d。兩組連續(xù)治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時(shí)間，血清白細(xì)胞介素-5（IL-5）、IL-17、基質(zhì)金屬蛋白酶-8（MMP-8）、IL-21和IL-22水平及ACQ-7、ACT和Marks-AQLQ評(píng)分。結(jié)果 經(jīng)治療，對照組有效率為84.31%，顯著低于治療組的98.04%（P<0.05）。經(jīng)治療，治療組癥狀改善時(shí)間明顯早于對照組（P<0.05）。經(jīng)治療，兩組血清IL-5、IL-17、MMP-8、IL-21、IL-22水平均顯著下降（P<0.05），且治療組降低更明顯（P<0.05）。經(jīng)治療，兩組ACQ-7評(píng)分和Marks-AQLQ評(píng)分明顯下降，而哮喘控制ACT評(píng)分明顯升高（P<0.05），且治療組患者評(píng)分明顯好于對照組（P<0.05）。結(jié)論 咳喘舒片聯(lián)合布地奈德福莫特羅吸入粉霧劑治療支氣管哮喘可有效改善患者臨床癥狀，降低氣道炎癥反應(yīng)，改善患者生存質(zhì)量。

Objective To explore the clinical efficacy of Kechuanshu Tablets combined with budesonide formoterol in the treatment of bronchial asthma. Methods Patients (102 cases) with bronchial asthma in Tianjin Ninghe District Hospital from February 2020 to February 2021 were divided into control and treatment groups based on union lotto method, and each group had 51 cases. Patients in the control group were administered with Budesonide and Formoterol Fumarate Powder for Inhalation (II), 2 press/time, and increased to 4 press if necessary, twice daily. Patients in the treatment group were po administered with Kechuanshu Tablets, 1 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, the serum levels of IL-5, IL-17, MMP-8, IL-21 and IL-22, and the scores of ACQ-7, ACT, and Marks-AQLQ in two groups before and after treatment were compared. Results After treatment, the effective rate in the control group was 84.31%, which was significantly lower than 98.04% in the treatment group (P<0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the serum levels of IL-5, IL-17, MMP-8, IL-21 and IL-22 were significantly decreased in two groups (P<0.05), especially in the treatment group (P<0.05). After treatment, the scores of ACQ-7 and Marks-AQLQ in two groups were significantly decreased, while the ACT score of asthma control were significantly increased (P<0.05), and these scores in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Kechuanshu Tablets combined with budesonide formoterol in the treatment of bronchial asthma can effectively improve the clinical symptoms, reduce airway inflammation and improve the quality of life of patients.

R974

天津市衛(wèi)生和計(jì)劃生育委員會(huì)科研課題（2016RB16251）